Chimerix (NASDAQ:CMRX) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Chimerix (NASDAQ:CMRX) from a sell rating to a hold rating in a report published on Tuesday morning, Zacks.com reports.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Other equities analysts have also issued research reports about the company. ValuEngine upgraded Chimerix from a sell rating to a hold rating in a research note on Thursday, August 1st. HC Wainwright lifted their target price on Chimerix from $5.00 to $7.00 and gave the company a buy rating in a research note on Thursday, August 1st. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $4.00.

Shares of Chimerix stock opened at $2.44 on Tuesday. The firm has a market cap of $145.82 million, a P/E ratio of -1.71 and a beta of 1.34. Chimerix has a 12 month low of $1.74 and a 12 month high of $4.40. The stock’s fifty day moving average price is $2.46 and its 200-day moving average price is $2.88.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.18). The firm had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.30 million. Chimerix had a negative net margin of 729.02% and a negative return on equity of 38.70%. As a group, research analysts forecast that Chimerix will post -1.1 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Quantitative Systematic Strategies LLC purchased a new position in Chimerix in the second quarter valued at about $67,000. SG Americas Securities LLC grew its stake in Chimerix by 105.4% in the first quarter. SG Americas Securities LLC now owns 20,590 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 10,567 shares during the last quarter. Susquehanna International Group LLP purchased a new position in Chimerix in the second quarter valued at about $92,000. Prudential Financial Inc. purchased a new position in Chimerix in the second quarter valued at about $104,000. Finally, Algert Global LLC purchased a new position in Chimerix in the second quarter valued at about $194,000. Institutional investors own 61.96% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Read More: What are benefits of a growth and income fund?

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.